Exhaled nitric oxide is decreased by exposure to the hyperbaric oxygen therapy environment.

UNLABELLED: Exhaled nitric oxide (eNO) detects airway inflammation. Hyperbaric oxygen therapy (HBOT) is used for tissue hypoxia, but can cause lung damage. We measured eNO following inhalation of oxygen at different tensions and pressures.
METHODS: Part 1, eNO was measured before and after HBOT. Part 2, normal subjects breathed 40% oxygen.
RESULTS: Baseline eNO levels in patients prior to HBOT exposure were significantly higher than in normal subjects (P < .05). After HBOT, eNO significantly decreased in patients (15.4 +/- 2.0 versus 4.4 +/- 0.5 ppb, P < .001), but not in normal subjects, after either 100% O2 at increased pressure or 40% oxygen, 1 ATA. In an in vitro study, nitrate/nitrite release decreased after 90 minutes HBOT in airway epithelial (A549) cells.
CONCLUSION: HBO exposure causes a fall in eNO. Inducible nitric oxide synthase (iNOS) may cause elevated eNO in patients secondary to inflammation, and inhibition of iNOS may be the mechanism of the reduction of eNO seen with HBOT.

INTRODUCTION

Exhaled nitric oxide (eNO) is a marker of airway inflammation [1]. Although NO is produced in the airways by a variety of cells, large amounts may be generated from those involved in the acute and chronic inflammatory responses [2]. NO plays a role in pulmonary host defence mechanisms, and is thought to have both bactericidal and bacteriostatic effects [3, 4]. Exhaled NO is released by nitric oxide synthases (NOS), including neuronal NOS (nNOS, Type 1), inducible NOS (iNOS, Type 2), and endothelial NOS (ecNOS, Type 3). These NOS isoforms have been demonstrated in the airways of many mammalian species including man [5, 6]. iNOS is generally not expressed unless the cells have been induced by certain cytokines, however, when stimulated, high concentrations (μM) of NO are produced [7-9]. Thus, an increase in exhaled NO may be due to upregulation of iNOS within epithelial cells in response to proinflammatory cytokines and oxidants [10, 11].

In recent years, eNO has been used as a sensitive marker of asthmatic airway inflammation [12, 13]. The assay is easy to perform and reproducible with clinically useful sensitivity and specificity [1].

Hyperbaric oxygen therapy (HBOT) is used for the treatment of a number of conditions associated with tissue hypoxia, including late radiation tissue injury and diabetic foot ulcers. These conditions are associated with hypoxia at the site of disease, and improving oxygenation may assist in the resolution of these lesions. Despite these beneficial effects, HBOT is associated with some undesirable side effects. Hyperoxia has long been associated with tissue damage and the development of lung diseases. The mechanism is not fully understood, but may be attributed to reactive oxygen species (producing oxygen free radicals, ROS) which induce the pulmonary cytochrome P450 enzymes [14-16]. This is supported by animal research into neonatal bronchopulmonary dysplasia, which has shown an arrest in alveolar and capillary development in positive pressure ventilated animals [17]. It has been reported that ventilation with atmospheric hyperoxia in isolated perfused lungs increased NO generation [18, 19]. Conflicting reports in the literature have been described in studies of humans breathing 100% O [20, 21]. These changes associated with hyperoxia have been explained by the bonding of oxygen free radicals (O) to extracellular NO in the body generating peroxynitrite (ONOO−) which is a strong oxidant and which has been reported to increase iNOS expression [22-25]. However, not all studies are consistent with these findings and hyperbaric oxygenation (HBO) has been shown to decrease NO generation in animal models of shock, perhaps via a decrease in the activity of iNOS [26].

This study aimed to measure alterations in eNO following a standard hyperbaric oxygen regime in those with tissue hypoxia and to compare them with normal subjects who were either attendants in the HBO chamber or who breathed supplemental oxygen at sea level. It was hypothesised that hyperoxia could downregulate exhaled nitric oxide. In addition it was hypothesised that the changes in eNO would be reflected in the ability of isolated pulmonary cells to generate nitrite in vitro under similar conditions as experienced by the patients.

METHODS

Subjects

Following the ethics committee's approval of the experimental protocol and written informed consent, patients undergoing HBO at the Prince of Wales Hospital Department of Diving and Hyperbaric Medicine were recruited to the study. All patients were undergoing HBOT for medical indications and no patient was subjected to HBOT purely for the sake of the study. These subjects were asked to complete a questionnaire detailing their medical history, current medications (particularly the use of glucocorticosteroids or nonsteroidal anti-inflammatory agents (NSAIDS)), and specific questions regarding the diagnoses of asthma, chronic obstructive pulmonary disease or other pulmonary diseases, diabetes mellitus, and ischemic heart disease. Smoking history was obtained. Normal subjects were recruited from hospital staff and also completed the same questionnaire.

Exhaled nitric oxide measurements

The sampling and measurement procedure was as follows: subjects were asked to inhale orally and exhale into a 2-liter gas impermeable bag with a one way valve, generating a positive pressure to close the velum [27, 28]. If unable to fill this in one breath, a second breath was used. The samples were then analysed within 60 minutes using a closed gas circuit connected to a chemiluminescent nitric oxide analyser, (Dasibi Environmental Corp, Glendale, Calif, USA) for NO and Spacelabs Capnograph Model 90513-30 (Redmond, Wash, USA) for CO. The values obtained are therefore an average of mixed expired gas concentrations of one or two expirations.

Protocol

Part one

All patients and attendants provided an expired NO sample prior to compression, the patients then underwent a standard 90-minute HBOT session at 2.4 atmospheres absolute (ATA), breathing 100% O. These sessions involve a five to ten minute compression phase breathing air, 90 minutes breathing 100% oxygen at 2.4 ATA by demand valve mask or hood, and a further 20 minutes slow decompression while continuing to breathe oxygen. The total time in the chamber for each session is therefore approximately two hours. During this period they were accompanied by a trained hyperbaric chamber nursing attendant who breathed air during the compression and 2.4 ATA periods, before starting 100% oxygen for the 20-minute decompression phase. This is a standard operating procedure to reduce the risk of decompression illness for the attendant. For our experimental protocol, the attendants supplied a further sample of expired gas at 2.4 ATA before starting their oxygen breathing period.

Immediately on exiting the hyperbaric chamber, a further exhaled NO sample was taken from patients and staff.

Part two

A separate section studied normal subjects breathing 40% oxygen for 90 minutes via a face mask at 1 ATA. Exhaled NO samples were collected every 15 minutes.

Part three

A549 cells, an immortalised cell line derived from a lung epithelial cell carcinoma, were used as a model of airway epithelium. These cells have been demonstrated to be able to express iNOS and to be able to generate nitrite [29]. Four plates of 2 − 4 × 106 A549 cells were incubated in F12-K media with 10% foetal calf serum (FCS) and exposed to the following conditions for 90 min: (a) room temperature and ambient air (plate A); (b) 100% oxygen at normal pressure (plate B); (c) air at 2.4 ATA pressure (plate C); and (d) 100% oxygen at 2.4 ATA (plate D). Interferon gamma is known to stimulate A549 cells to increase NO production [30]. Under each of the conditions, A549 cells were therefore cultured in media with 0, 10, and 20 ng/mL recombinant human interferon gamma (hIFN γ, Serotec Ltd, UK). Nitrite/nitrate (NOx) was measured by using a fluorescent method [31]. Samples were mixed with NADPH, FAD (Sigma, Sydney, Australia), and nitrate reductase with a final concentration of 50 μM, 5 μM, and 50 IU/L, respectively, and incubated in 37°C for 1 h, which allows nitrate to be converted to nitrite. Nitrite was conjugated with 0.05 mg/mL 2,3-diaminonaphthalene (DAN) in 0.62 M HCL to allow quantification by fluorescence. The reaction was terminated with 2.8 M NaOH. The resultant fluorescence was immediately read on a CytoFluro Series 4000, Multiwell Plate Reader (Perseptive Biosystems, Mass, USA) at excitation 360/40, emission 395/25, gain 50, limit of detection 2 μmol/L, mean (SD) intra-assay coefficient of variation 3.11(3.42)%. Data are expressed as % change from baseline.

Analysis

Data are presented as mean ± SE. The results were analysed using changes in NO (ppb) and CO (mmHg), after the NO values were log transformed to the normal distribution [13]. Student's t test was used to calculate P-values, which were considered significant if P < .05.

RESULTS

Part one

In total, 16 attendants and 15 patients were recruited. Of the patients, 12 were not on current glucocorticosteroid therapy and 10 were not current steroid or NSAID users (Table 1). One attendant omitted to collect a breath sample in the chamber and other two samples collected in the chamber were lost due to overexpansion and ultimate failure of the gas collection bag during decompression. Mean (SD) coefficient of variation of interbag exhaled NO levels was 6.36(1.17)%.

Table 1

Subject characteristics.

	Patients	Normal controls
	(male/female)	(male/female)
Smoker	1/0	0/0
Ex-smoker	0/0	2/0
Nonsmoker	9/5	6/8
Asthma	1/0	0/0
NSAID	2/0	0/0
Steroids	2/1	0/0
Foot ulcers	6	0
Osteoradionecrosis	7	0
Dental caries	1	0
Radiation cystitis	1	0
Lumbar cord oedema	1	0
Total	10/5	8/8

The initial mean eNO level in patients was significantly higher than both that in attendants (15.4 ± 2.0 ppb vs 7.6 ± 1.1 ppb, P < .05) and the normal subjects in Part 2 (5.3 ± 1.0 ppb, P < .01). No difference in the initial exhaled NO level was found between the attendants and normal subjects at 1 ATA (7.6 ± 1.1 ppb vs 5.3 ± 1.0 ppb, resp, P = .14).

Patients

eNO significantly decreased after HBOT (Figure 1, 15.4 ± 2.0 vs 4.4 ± 0.5 ppb, P < .001, n = 15). This effect was present in both the subgroup not on glucocorticosteroids (15.2 ± 2.3 vs 4.3 ± 0.6 ppb, P < .001, n = 12) and in the subgroup on neither glucocorticosteroids nor NSAIDs (16.1 ± 2.5 vs 4.4 ± 0.6 ppb, P < .001, n = 10). Exhaled CO showed a small but significant increase following HBOT in the patient group (25.5 mmHg ± 1.0 vs 27.3 mmHg ± 0.9, P < .05).

Figure 1

Exhaled nitric oxide levels in 15 patients undergoing HBOT immediately before and after treatment. There was a significant fall in these patients (mean ± SE, before 15.4 ± 2.0 ppb, afterwards 4.4 ± 0.5 ppb, P < .001).

Attendants in the hyperbaric chamber

The mean exhaled NO level before hyperbaric exposure was 7.6 ± 1.1 ppb and the mean level was 7.9 ± 0.9 ppb (Figure 2, P = .46, n = 16) afterwards.

Figure 2

Exhaled nitric oxide levels in 16 normal staff members who were exposed to the hyperbaric environment but did not use oxygen until immediately prior to decompression. There were no significant changes between the samples.

Part two

Normal subjects breathing 40% oxygen at 1 ATA

Mean exhaled NO levels in this normal group of subjects were 5.3 ± 1.0 ppb before and 4.6 ± 1.1 after 90-minute 40% oxygen inhalation (P = .22, n = 8), with no significant change in exhaled NO levels at any of the 15-minute intervals.

Part three

There was a significant decrease in NOx release into the cell culture media after exposure to 100% oxygen for 90 minutes in the A549 cells incubated in media alone (32.49% change from baseline vs 9.38%, P < .01) and media with 20 ng/mL hIFN γ (33.58% vs 9.25%, P < .05). The hyperbaric environment alone did not cause significant changes (32.49% vs 22.80%, P = .32 in media only, and 33.58% vs 20.64%, P = .29 in media with 20 ng/mL hIFN γ).

DISCUSSION

In this study, eNO levels of patients were significantly decreased after HBOT. In normal subjects eNO did not decrease significantly after either a short exposure to 100% oxygen during decompression, or 40% oxygen for 90 minutes in normal subjects. The decrease in eNO seen in the HBOT patient group has been observed in studies using oxygen at 1 ATA. For example, Tsuchiya demonstrated inhalation of 100% oxygen for 50 minutes reduced exhaled NO levels while inhalation of 40% oxygen in a second group of mechanically ventilated human subjects undergoing surgery did not [21]. It is possible, however, that endogenous NO might be affected by anaesthetic agents, surgery, the increased airway pressure during mechanical ventilation, and these individuals may not show the same response as spontaneously breathing individuals. It is worth noting that both our study and that of Tsuchiya showed that 40% oxygen inhalation did not change eNO levels significantly [21]. The 40% oxygen inhalation was chosen as it allowed a conventional mask to be used, but it would have been a more accurate comparison of the equivalent 2.4 ATA exposure if 50.4% oxygen had been used.

In Part 1 of this study, no significant changes in eNO levels were observed in normal subjects after breathing hyperbaric air at 2.4 ATA for 90 minutes. This exposure is equivalent to breathing 50.4% oxygen at 1 ATA (the inspired pO2 is approximately 361 mmHg in each case). Compared with the hyperbaric oxygen at the same pressure inhaled by the patients, it could be concluded that pressure is not the main factor altering the eNO levels in this study, although these normal subjects had a lower baseline eNO.

The increase in exhaled CO in the patients is presumably due to either stimulation of NADPH turnover through the pentose cycle or, more likely, suppression of their hypoxic ventilatory drive [32-34].

The attendants received less hyperbaric oxygen exposure than the patients and we acknowledge this may bias the result towards no change in these individuals. In addition, this group was younger and generally more physically fit. The lack of inflammatory diseases in both control groups probably accounts for the difference in baseline eNO between them and the patients. Half of the patients had osteoradionecrosis of the head and neck, initial mean exhaled NO 15.0 ± 2.88 ppb, which may be associated with inflammation of the upper airway. Those without osteoradionecrosis, however, had a similar baseline exhaled NO. The reason for this is unclear but may be related to inflammation associated with their underlying condition with foot ulcers being the most common indication for HBOT. These conditions were associated with an elevated eNO above our normal range [35]. Although this was a prospective study, patients were recruited at various times during their HBOT, which may have influenced the baseline exhaled NO values. It was hypothesised that the elevated baseline exhaled NO in the patients was related to the induction of iNOS. Inducible NOS is generally not expressed unless the cells have been activated by inflammatory cytokines [7–9, 36, 37].

Inhibition of iNOS in patients by HBOT may account for the decrease of eNO levels. Recent studies have demonstrated that oxidative stress also prevented iNOS induction in intestinal epithelial cells [38, 39]. Yuan et al showed that hyperbaric oxygen (HBO) suppressed iNOS expression in rabbit chondrocytes, and Pedoto et al reported that HBO decreased exhaled NO generation, plasma nitrite/nitrate concentration, and iNOS expression in the rat lung [26, 38, 40]. Absent or low levels of iNOS in normal subjects could explain why eNO levels did not change after oxygen inhalation.

Changes in production of ROS or inhibition of iNOS expression would be two possible reasons for the decrease in eNO after inhalation of high concentrations of oxygen for a long period although no study has addressed the effect of short exposure to HBOT in terms of oxidative status [41]. ROS generally increase inflammation, which would be expected to increase iNOS expression. It is possible, however, that ROS could react with NO, and convert it to other NOx species. This seems unlikely as the in vitro studies showed a decline in NOx with O exposure.

It has been reported that a combination of interferon gamma and interleukin 4 stimulates and maintains iNOS expression in human airway epithelium [42]. This study showed that NOx released from the A549 cell line incubated in media alone or with 20 ng/mL human interferon gamma significantly decreased after exposure to 100% oxygen, which occurred in the absence of HBO. This suggests that inhibition of iNOS may be the mechanism of the reduction in eNO seen in patients. It has been demonstrated that iNOS is expressed under resting conditions in the A549 cell line, which could explain the decrease in NOx release after 100% oxygen exposure in the A549 cell line incubated in media only [29].

In conclusion, our results suggest that inhibition of iNOS may be the mechanism of HBOT-induced reduction in eNO. This might have beneficial effects on inflammation, a question which could to be further investigated by measurement of iNOS expression in a randomized controlled study in response to hyperoxia.